FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.

Renata A TassiAngela GambinoLaura ArdighieriEliana BignottiPaola TodeschiniChiara RomaniLaura ZanottiMattia BugattiFulvio BorellaDionyssios KatsarosGermana TognonEnrico SartoriFranco OdicinoChiara RomualdiAntonella Ravaggi

Published in: British journal of cancer (2019)

We demonstrated the possible involvement of FXYD5 and ECM-receptor interaction signal pathway in HCSOC survival and prognosis.

Keyphrases

high grade
low grade
free survival
poor prognosis
signaling pathway
binding protein
extracellular matrix
long non coding rna